Document is current
Any future updates will be listed below
-
Authors
Wenzel, Jan-Per https://orcid.org/0000-0002-6302-8671
Albrecht, Jan-Niklas
Toprak, Betül
Petersen, Elina
Nikorowitsch, Julius
Cavus, Ersin
Jahnke, Charlotte
Riedl, Katharina Alina
Adam, Gerhard
Twerenbold, Raphael
Blankenberg, Stefan
Kirchhof, Paulus
Lund, Gunnar
Tahir, Enver
Müllerleile, Kai
Radunski, Ulf K.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03934957 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of Sex and Cardiovascular Risk Factors on Myocardial T1, Extracellular Volume Fraction, and T2 at 3 Tesla: Results From the Population-Based, Hamburg City Health Study
https://doi.org/10.1161/circimaging.122.014158
Head-to-head comparison of cardiac magnetic resonance imaging and transthoracic echocardiography in the general population (MATCH)
https://doi.org/10.1007/s00392-025-02660-1
-
Funding
Funding for this research was provided by:
Deutsche Stiftung für Herzforschung (F/29/19)
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
- License Information
-
More Information
Article History
Received: 9 September 2024
Accepted: 21 April 2025
First Online: 12 May 2025
Declarations
:
: The authors declare that they have no competing interests. The authors do hereby declare that their study complies with the Declaration of Helsinki. JPW received funding of the German Foundation of Heart Research (F/29/19), speaker fees from Abbott and Doctrina Med, and travel grants from Boston Scientific in each case unrelated to this project. SB reports honoraria from Abbott, Siemens, Thermo Fisher, and Roche, outside of the submitted work. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years. PK is listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783).
: HCHS was approved by the local ethics committee (PV5131, State of Hamburg Chamber of Medical Practitioners). This study was approved by the review board of the HCHS. All participants gave written informed consent. This study and the HCHS were conducted in accordance with the Declaration of Helsinki.
: Not applicable.
